2005
The curse of the cure
DeVita V. The curse of the cure. Nature Reviews Clinical Oncology 2005, 2: 1-1. PMID: 16264829, DOI: 10.1038/ncponc0054.Peer-Reviewed Original Research
1997
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo D, Glatstein E, Duffey P, Young R, Ihde D, Bastian A, Wilson W, Wittes R, Jaffe E, Hubbard S, DeVita V. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Journal Of Clinical Oncology 1997, 15: 3338-46. PMID: 9363863, DOI: 10.1200/jco.1997.15.11.3338.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedPrednisoneProcarbazineProspective StudiesTreatment OutcomeVinblastineVincristineConceptsMantle field radiation therapyDisease-free survivalLarge mediastinal massMediastinal Hodgkin's diseaseHodgkin's diseaseABVD chemotherapyRadiation therapyOverall survivalMediastinal massMOPP/ABVDSecond solid tumorsTreatment-related pneumonitisComplete response rateAnn Arbor stageClinical prognostic factorsErythrocyte sedimentation rateTreatment of patientsAge 35 yearsLactate dehydrogenase levelsABVD therapyDacarbazine (ABVD) chemotherapyMedian followMOPP chemotherapySalvage therapyB symptoms
1993
Lymphomas.
Kwak L, DeVita V, Longo D. Lymphomas. 1993, 14: 383-426. PMID: 8312110.Peer-Reviewed Original Research
1992
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E, Phares J, Jaffe E, Urba W, DeVita V. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. Journal Of Clinical Oncology 1992, 10: 210-8. PMID: 1732422, DOI: 10.1200/jco.1992.10.2.210.Peer-Reviewed Original ResearchConceptsComplete response rateInitial remissionComplete remissionCombination chemotherapyHodgkin's diseaseSalvage therapyOverall survivalPeripheral blood stem cell supportResponse rateChemotherapy-induced complete remissionConventional-dose salvage therapyDate of relapseDurable second remissionsRemission 5 yearsSalvage combination chemotherapyShort initial remissionTreatment-related complicationsDisease-free survivalClinical prognostic factorsStem cell supportDuration of responsePrimary treatment regimenRelapse of patientsNational Cancer InstituteB symptomsThe use of combination chemotherapy in the treatment of early stage Hodgkin's disease.
Longo D, DeVita V. The use of combination chemotherapy in the treatment of early stage Hodgkin's disease. Important Advances In Oncology 1992, 155-65. PMID: 1582671.Peer-Reviewed Original Research
1991
Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Longo D, Russo A, Duffey P, Hubbard S, Glatstein E, Hill J, Jaffe E, Young R, DeVita V. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal Of Clinical Oncology 1991, 9: 227-35. PMID: 1988570, DOI: 10.1200/jco.1991.9.2.227.Peer-Reviewed Original ResearchConceptsMediastinal Hodgkin's diseaseDisease-free survivalComplete respondersModality treatmentHodgkin's diseaseNational Cancer InstituteComplete remissionRadiation therapyMantle radiation therapyStage IIB diseaseOverall survival differenceMOPP chemotherapyDurable remissionsIIB diseaseLate complicationsModality therapyOverall survivalComplete responseMediastinal massSubsequent therapyTumor mortalitySurvival differencesChest radiographsRetrospective analysisMaximal response
1986
Twenty years of MOPP therapy for Hodgkin's disease.
Longo D, Young R, Wesley M, Hubbard S, Duffey P, Jaffe E, DeVita V. Twenty years of MOPP therapy for Hodgkin's disease. Journal Of Clinical Oncology 1986, 4: 1295-306. PMID: 3528400, DOI: 10.1200/jco.1986.4.9.1295.Peer-Reviewed Original ResearchConceptsEnd of treatmentHodgkin's diseaseComplete responseDisease patientsLymphocyte-depleted typeHodgkin's disease patientsHigher CR rateResults of treatmentMOPP therapyB symptomsIntercurrent illnessComplete remissionLonger remissionsCR rateHodgkin's lymphomaLonger survivalBiopsy specimensPatientsHigh dosesDiseaseRemissionLymphomaMore cyclesTreatmentLarge cells
1984
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsHodgkin's diseaseMalignant neoplasmsSolid tumorsNational Cancer Institute ExperienceChronic myeloid leukemiaCases of sarcomaRisk of leukemiaUntreated patientsPatient ageHodgkin's lymphomaMedical recordsInstitute experienceMyeloid leukemiaSimilar riskAge 40Treatment groupsPatientsGreater riskLeukemiaTen yearsDiseaseTumorsLymphomaPositive association
1982
Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction
Miliauskas J, Berard C, Young R, Garvin A, Edwards B, Devita V. Undifferentiated non‐Hodgkin'S lymphomas (Burkitt's and non‐Burkitt's types). The relevance of making this histologic distinction. Cancer 1982, 50: 2115-2121. PMID: 7127252, DOI: 10.1002/1097-0142(19821115)50:10<2115::aid-cncr2820501024>3.0.co;2-9.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaMedian ageStage IVPrimary siteHistologic distinctionIntra-abdominal involvementFive-year survivalNational Cancer InstituteMedian survivalBurkitt's typeRetrospective studyHodgkin's lymphomaPatient populationLonger survivalCancer InstituteLymphomaPatientsSurvivalDiseaseMonthsAgePresentationYearsCasesHodgkin's disease: conference summary and future directions.
DeVita V. Hodgkin's disease: conference summary and future directions. Journal Of The National Cancer Institute 1982, 66: 1045-55. PMID: 7074631.Peer-Reviewed Original Research
1981
Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981, 58: 45-51. PMID: 7236892, DOI: 10.1182/blood.v58.1.45.bloodjournal58145.Peer-Reviewed Original ResearchConceptsLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosisClinical trials
1980
Non-Hodgkin's lymphomas in leukemic phase: Clinicopathologic correlations
Come S, Jaffe E, Andersen J, Mann R, Johnson B, DeVita V, Young R. Non-Hodgkin's lymphomas in leukemic phase: Clinicopathologic correlations. The American Journal Of Medicine 1980, 69: 667-674. PMID: 7001897, DOI: 10.1016/0002-9343(80)90416-7.Peer-Reviewed Original ResearchConceptsPeripheral blood involvementBlood involvementHistologic subtypeLeukemic phaseAdult lymphoblastic lymphomaDiffuse large cell lymphomaNon-Hodgkin lymphomaLarge cell lymphomaHomogeneous clinical pictureTypes of NHLLymphoblastic lymphomaRappaport classificationClinical pictureClinicopathologic entityHodgkin's lymphomaNodular lymphomaUnresponsive diseaseClinicopathologic correlationLymphocytic lymphomaClinical subtypesLeukemic conversionCell lymphomaCytologic featuresHigh riskPredominant cells
1978
Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy
Young R, Canellos G, Chabner B, Hubbard S, Devita V. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978, 42: 1001-1007. PMID: 688174, DOI: 10.1002/1097-0142(197808)42:2+<1001::aid-cncr2820420723>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsPatterns of relapseAdvanced Hodgkin's diseaseComplete remissionCombination chemotherapyHodgkin's diseasePrevious diseaseNodal sitesNodular sclerosis histologyProphylactic radiation therapyLeft supraclavicular areaSite of diseaseNodal diseaseSystemic symptomsSupraclavicular areaRadiation therapyRelapse increasesNodal areasPatientsRelapseDiseaseRemissionChemotherapyHistologyTherapy
1977
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Anderson T, Bender R, Fisher R, DeVita V, Chabner B, Berard C, Norton L, Young R. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Journal Of The National Cancer Institute 1977, 61: 1057-66. PMID: 71205.Peer-Reviewed Original ResearchAdolescentAdultAgedBleomycinChildClinical Trials as TopicCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHumansLymphomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission, SpontaneousTime FactorsVincristineThe treatment of Hodgkin's disease
Young R, Anderson T, DeVita V. The treatment of Hodgkin's disease. Current Problems In Cancer 1977, 1: 1-29. PMID: 66119, DOI: 10.1016/s0147-0272(77)80009-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultBleomycinBone MarrowChildClinical Trials as TopicDrug Therapy, CombinationFemaleHodgkin DiseaseHumansLaparoscopyLaparotomyLiverLymph NodesMaleMechlorethamineNational Institutes of Health (U.S.)Neoplasms, Multiple PrimaryPrednisoneProcarbazineRadiotherapy, High-EnergySpleenSplenectomyUnited StatesVincristine
1976
Combined modality treatment of American Burkittapos;s lymphoma
Ziegler J, Devita V, Graw R, Herzig G, Leventhal B, Levine A, Pomeroy T. Combined modality treatment of American Burkittapos;s lymphoma. Cancer 1976, 38: 2225-2231. PMID: 1036716, DOI: 10.1002/1097-0142(197612)38:6<2225::aid-cncr2820380606>3.0.co;2-f.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaCombined modality treatmentBone marrow autograftsMajor therapeutic goalPrevention of relapseThird remissionFirst remissionIntensive chemotherapyComplete responseModality treatmentInitial treatmentAmerican patientsMarrow autograftsRisk factorsClinical trialsTherapeutic goalsPatientsLymphomaRemissionChemotherapyTreatmentImmunotherapyRelapseRadiotherapyAutograftTreatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine.
Young R, DeVita V. Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine. National Cancer Institute Monograph 1976, 43: 193-200. PMID: 1087955.Peer-Reviewed Original ResearchConceptsPyrimethamine-sulfadiazinePneumocystis pneumoniaPentamidine isethionateClinical trialsPneumocystis carinii pneumoniaManagement of patientsSeverely ill patientsRandomized clinical trialsCarinii pneumoniaLocal toxicityRegimensIll patientsPatientsComplete recoveryPneumoniaPneumocystisIsethionateComparative toxicityTrialsPentamidineToxicityA Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors
Robinson R, DeVita V, Levy H, Baron S, Hubbard S, Levine A. A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors. Journal Of The National Cancer Institute 1976, 57: 599-602. PMID: 978771, DOI: 10.1093/jnci/57.3.599.Peer-Reviewed Original ResearchConceptsSolid tumorsSerum glutamic oxaloacetic transaminaseSerum glutamic pyruvic transaminaseSeparate drug trialsObjective tumor responseDetectable serum levelsRoute of administrationChronic myelogenous leukemiaLow serum concentrationsGlutamic oxaloacetic transaminaseGlutamic pyruvic transaminasePolyriboinosinic-polyribocytidylic acidPoly I-poly CInducers of interferonCoagulation abnormalitiesSerum levelsMultiple dosesSerum concentrationsTumor responseAcute leukemiaDrug trialsBlast crisisMyelogenous leukemiaTransient elevationDrug doseChemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy.
Canellos G, DeVita V, Whang-Peng J, Chabner B, Schein P, Young R. Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. Blood 1976, 47: 1003-9. PMID: 1064434, DOI: 10.1182/blood.v47.6.1003.bloodjournal4761003.Peer-Reviewed Original ResearchConceptsChromosome-positive chronic granulocytic leukemiaChronic granulocytic leukemiaBlastic phaseComplete remissionPrior splenectomyComplete remittersGranulocytic leukemiaCytosine arabinosidePhiladelphia chromosome-positive chronic granulocytic leukemiaNonsplenectomized groupPrednisone groupPartial remissionMedian survivalElective splenectomyPartial responseSecondary therapyChronic phaseOpposite regimenRemissionSplenectomyVincristinePrednisoneChemotherapyPatientsCell linesPneumocystis Pneumonia
MICHAELIS L, LEIGHT G, POWELL R, DEVITA V. Pneumocystis Pneumonia. Annals Of Surgery 1976, 183: 301-306. PMID: 1083218, PMCID: PMC1344242, DOI: 10.1097/00000658-197603000-00016.Peer-Reviewed Original ResearchConceptsOpen lung biopsyMajor surgical proceduresSmall anterior thoracotomyCause of deathEarly thoracotomyAnterior thoracotomyLung biopsyMost patientsPulmonary infectionIll patientsSusceptible patientsInappropriate therapyGeneral anesthesiaInfected patientsPneumocystis pneumoniaHematologic malignanciesTherapeutic courseSurgical proceduresEffective treatmentPatientsPneumocystis cariniiInfectionThoracotomyTreatmentImmediate identification